Related Experiment Video
Updated: Mar 30, 2026
13:45
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
10.5K
Post-transplant Merkel Cell Carcinoma
Virve Koljonen1, Helka Sahi, Tom Böhling
1Department of Plastic Surgery, University of Helsinki and Helsinki University Hospital, FIN-00290 Helsinki, Finland. virve.koljonen@hus.fi, virve.koljonen@gmail.com.
Acta Dermato-Venereologica
|November 12, 2015
Summary
Organ transplant recipients face a significantly higher risk of Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer. This review details MCC
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Malignant tumors are a primary complication of immunosuppressive therapy.
- Organ transplant recipients (OTRs) face unique challenges due to immunosuppression.
- Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer linked to Merkel cell polyomavirus.
Purpose of the Study:
- To review the etiology and current treatment of Merkel cell carcinoma (MCC).
- To highlight the increased incidence and poorer survival of MCC in immunosuppressed individuals, particularly OTRs.
- To educate transplant physicians on diagnosing and managing MCC in their patients.
Main Methods:
- Comprehensive literature review of MCC in immunosuppressed patients.
- Analysis of reported cases in organ transplant recipients.
- Synthesis of current diagnostic and therapeutic recommendations.
Main Results:
- MCC occurs 66-182 times more frequently in OTRs than the general population.
- 79 cases of MCC in OTRs are documented in the current literature.
- Immunosuppressed individuals exhibit worse MCC-specific survival rates.
Conclusions:
- MCC is a significant concern for organ transplant recipients due to increased risk and poorer outcomes.
- Awareness and updated management strategies are crucial for transplant physicians.
- Further research is needed to optimize MCC treatment in immunosuppressed populations.
